Figure S9 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Yuying Zhang; Jinbang Li; Xiaoyu Guo; Zhao Gao; Ji‐An Pan; Sheng Nong; Jin-Lin Ma; Gang Chen; Jiali Zhang

doi:10.1158/0008-5472.30029704

September 2, 2025Open Access

Figure S9 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

View Full Paper

Ask AI

Bookmark

Share

Key Points

Higher C/S ratio correlates with better pathological response to anti-PD1 therapy.
Tumor-specific MHC-II activates both CD4 and CD8 T cells, boosting overall therapy effectiveness.
Analysis indicates potential strategies to enhance immunotherapy outcomes in cancer treatment.
Findings support the need for personalized approaches in targeting head and neck squamous cell carcinoma.

Implication

Observational analysis reveals a higher C/S ratio correlates with improved pathological response to anti-PD1 therapy in head and neck cancer, suggesting enhanced immunotherapy efficacy.

Abstract

The relationship between the C/S ratio and pathological response to anti-PD1 therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b74 https://doi.org/10.1158/0008-5472.30029704

View Full Paper

Ask AI

Bookmark

Share

Figure S9 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S9 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading